A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

on behalf of the Taiwan Cooperative Oncology Group

Research output: Contribution to journalArticlepeer-review

99 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences